Labcorp Holdings Inc. (LH) Financial Statements
Historical financial data — 37 statements covering FY2016–FY2025
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offer...
Labcorp Holdings Inc.'s revenue increased 7.2% year over year, from $13.01B to $13.95B.
Net income increased 17.5% over the same period, from $746.0M to $876.5M.
Over the 9-year period from FY2016 to FY2025, revenue grew by 45% in total.
Total debt remained relatively stable at $5.08B.
The debt-to-equity ratio stands at 0.59, indicating a moderate leverage profile.
Operating cash flow grew 3.4% to $1.64B.
Labcorp Holdings Inc. maintains a moderate net profit margin of 6.3%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2023 | $9.13B+141.6% | $585.1M | $2.54B | $848.4M | $748.1M | $16.89B | $4.43B | $7.87B |
| Q1 FY2024 | $3.18B-65.2% | $228.0M | $897.3M | $321.3M | $-29.8M | $16.53B | $3.05B | $7.96B |
| Q2 FY2024 | $6.40B+101.4% | $433.3M | $1.82B | $616.1M | $531.3M | $16.71B | $3.05B | $8.01B |
| Q3 FY2024 | $9.68B+51.3% | $602.6M | $2.73B | $870.2M | $808.6M | $18.61B | $5.35B | $8.17B |
| Q1 FY2025 | $3.35B-65.4% | $212.8M | $948.0M | $326.0M | $18.5M | $17.60B | $5.57B | $8.31B |
| Q2 FY2025 | $6.87B+105.4% | $450.7M | $1.99B | $720.5M | $639.1M | $18.06B | $5.08B | $8.47B |
| Q3 FY2025 | $10.44B+51.9% | $711.8M | $3.02B | $1.12B | $1.03B | $18.26B | $5.08B | $8.70B |
| Q1 FY2026 | $3.54B-66.1% | $277.8M | $1.01B | $380.8M | $191.5M | $19.09B | $5.83B | $8.73B |
Balance Sheet Summary (Latest Period)
Total Assets
$18.39B
Total Liabilities
$9.76B
Total Equity
$8.62B
Cash & Equivalents
$532.3M
Total Debt
$5.08B
Current Assets
$4.02B
Current Liabilities
$2.82B
Retained Earnings
$8.64B